Eagle Pharmaceuticals - EGRX Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Eagle Pharmaceuticals in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" EGRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EGRX, but not buy additional shares or sell existing shares.
View EGRX analyst ratings or view top-rated stocks.

1 equities research analysts have issued 1 year price targets for Eagle Pharmaceuticals' shares. Their EGRX share price forecasts range from $51.00 to $51.00. On average, they predict the company's share price to reach $51.00 in the next year. This suggests a possible upside of 31.3% from the stock's current price.
View analysts price targets for EGRX or view top-rated stocks among Wall Street analysts.

Eagle Pharmaceuticals' stock was trading at $50.92 on January 1st, 2022. Since then, EGRX stock has decreased by 23.7% and is now trading at $38.84.
View the best growth stocks for 2022 here.

Eagle Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022.
View our EGRX earnings forecast.

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) announced its quarterly earnings data on Tuesday, November, 9th. The specialty pharmaceutical company reported $0.56 earnings per share for the quarter, topping the consensus estimate of ($0.44) by $1.00. The specialty pharmaceutical company had revenue of $39.85 million for the quarter, compared to the consensus estimate of $46.70 million. Eagle Pharmaceuticals had a net margin of 14.56% and a trailing twelve-month return on equity of 18.56%. During the same quarter in the prior year, the firm posted $0.51 earnings per share.

Based on aggregate information from My MarketBeat watchlists, some companies that other Eagle Pharmaceuticals investors own include Gilead Sciences (GILD), Exelixis (EXEL), Teekay Tankers (TNK), AbbVie (ABBV), Intercept Pharmaceuticals (ICPT), Radius Health (RDUS), bluebird bio (BLUE), Clovis Oncology (CLVS), GW Pharmaceuticals (GWPH) and Incyte (INCY).

Eagle Pharmaceuticals trades on the NASDAQ under the ticker symbol "EGRX."

Eagle Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Smith Graham & Co. Investment Advisors LP (1.82%), Allspring Global Investments Holdings LLC (1.63%), Scout Investments Inc. (1.15%), Assenagon Asset Management S.A. (0.65%), Los Angeles Capital Management LLC (0.27%) and Exchange Traded Concepts LLC (0.24%).
View institutional ownership trends.

Shares of EGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EGRX stock can currently be purchased for approximately $38.84.

Eagle Pharmaceuticals (NASDAQ:EGRX) has a market capitalization of $494.82 million and generates $171.55 million in revenue each year. The specialty pharmaceutical company earns $-8,630,000.00 in net income (profit) each year or $2.77 on an earnings per share basis.

Eagle Pharmaceuticals employs 102 workers across the globe.

Eagle Pharmaceuticals' mailing address is 50 TICE BOULEVARD SUITE 315, WOODCLIFF LAKE NJ, 07677. The official website for the company is www.eagleus.com. The specialty pharmaceutical company can be reached via phone at (201) 326-5300 or via email at investors@eagleus.com.